Structure of 5198-88-9
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 5198-88-9 |
Formula : | C4H2BrNO2S |
M.W : | 208.03 |
SMILES Code : | O=C(C1=CSC(Br)=N1)O |
MDL No. : | MFCD04115729 |
InChI Key : | BEGREHRAUWCAHV-UHFFFAOYSA-N |
Pubchem ID : | 2763209 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Num. heavy atoms | 9 |
Num. arom. heavy atoms | 5 |
Fraction Csp3 | 0.0 |
Num. rotatable bonds | 1 |
Num. H-bond acceptors | 3.0 |
Num. H-bond donors | 1.0 |
Molar Refractivity | 36.77 |
TPSA ? Topological Polar Surface Area: Calculated from |
78.43 Ų |
Log Po/w (iLOGP)? iLOGP: in-house physics-based method implemented from |
1.13 |
Log Po/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by |
1.84 |
Log Po/w (WLOGP)? WLOGP: Atomistic method implemented from |
1.6 |
Log Po/w (MLOGP)? MLOGP: Topological method implemented from |
0.1 |
Log Po/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by |
2.27 |
Consensus Log Po/w? Consensus Log Po/w: Average of all five predictions |
1.39 |
Log S (ESOL):? ESOL: Topological method implemented from |
-2.63 |
Solubility | 0.483 mg/ml ; 0.00232 mol/l |
Class? Solubility class: Log S scale |
Soluble |
Log S (Ali)? Ali: Topological method implemented from |
-3.11 |
Solubility | 0.162 mg/ml ; 0.000781 mol/l |
Class? Solubility class: Log S scale |
Soluble |
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by |
-1.53 |
Solubility | 6.2 mg/ml ; 0.0298 mol/l |
Class? Solubility class: Log S scale |
Soluble |
GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg |
High |
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg |
No |
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) |
No |
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) |
No |
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) |
No |
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) |
No |
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) |
No |
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) |
No |
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from |
-6.26 cm/s |
Lipinski? Lipinski (Pfizer) filter: implemented from |
0.0 |
Ghose? Ghose filter: implemented from |
None |
Veber? Veber (GSK) filter: implemented from |
0.0 |
Egan? Egan (Pharmacia) filter: implemented from |
0.0 |
Muegge? Muegge (Bayer) filter: implemented from |
1.0 |
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat |
0.56 |
PAINS? Pan Assay Interference Structures: implemented from |
0.0 alert |
Brenk? Structural Alert: implemented from |
0.0 alert: heavy_metal |
Leadlikeness? Leadlikeness: implemented from |
No; 1 violation:MW<1.0 |
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) |
2.65 |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
72% | With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; at 80℃; for 3h; | Example 8; Preparation of Compound 8 EPO <DP n="85"/>8Step 1 - Preparation of Intermediate Compound ATo a solution of 2-bromo-thiazole-4-carboxylic acid (2.0 mmol, 0.42 g) in DMF (10 ml_) was added λ/,λ/-diisopropylethylamine (3.0 mmol, 0.52 mL) followed by HATU (2.0 mmol, 0.76 g). To the resulting solution was added 4-(2-aminophenyl)- piperazine-1 -carboxylic acid te/t-butyl ester (2.0 mmol, 0.56 g) and the resulting reaction was heated to 80 C and allowed to stir at this temperature for 3 hours, after which time the reaction mixture was cooled to room temperature, then concentrated in vacuo Xo provide a crude residue. The crude residue was purified using flash flash column chromatography on silica gel using Hexane/EtOAc (4.5/1 ) as eluent to provide Compound A as a yellow solid (72%, 0.67 g). 1H NMR (400 MHz, CDCI3) δ 10.38 (S1 1 H), 8.49 (dd, J= 8.0, 1.2 Hz, 1 H), 8.14 (s, 1 H), 7.23-7.10 (m, 3 H), 3.72 (br s, 4H), 2.89-2.87 (m, 4H), 1.50 (s, 9H). HPLC-MS retention time = 2.39 min. m/z 467.05 (M+H). |
72% | With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; at 80℃; for 3h; | Example 1; Preparation of Intermediate Compound A; To a solution of 2-bromo-thiazole-4-carboxylic acid (2.0 mmol, 0.42 g), N1N- diisopropylethylamine (3.0 mmol, 0.52 mL) and HATU (2.0 mmol, 0.76 g) in DMF (10 mL) was added 4-(2-aminophenyl)-piperazine-1 -carboxylic acid fe/t-butyl ester (2.0 mmol, 0.56 g). The reaction mixture was stirred at 80 C for 3 h, and then concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel (eluent: Hexane:EtOAc (4.5:1)) to provide Compound A as a yellow solid (0.67 g , 72%). 1H NMR (400 MHz, CDCI3) δ 10.38 (s, 1 H), 8.49 (dd, J = 8.0, 1.2 Hz, 1 H), 8.14 (s, 1 H), 7.23-7.10 (m, 3 H), 3.72 (br s, 4H), 2.89-2.87 (m, 4H), 1.50 (s, 9H). HPLC-MS RT= 2.39 min, mass calculated for formula C19H23BrN4O3S 466.07, observed LCMS m/z 467.05 (M+H). |
With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; at 80℃; for 15h; | Example 5Preparation of Compound 5To a solution of 2-bromo-thiazole-5-carboxylic acid (0.050 mmol, 10 mg), λ/,λ/-diisopropylethylamine (0.20 mmol, 26 mg) and HATU (0.050 mmol, 19 mg) in DMF (1 ml_) was added 4-(2-aminophenyl)-piperazine-1-carboxylic acid tert-butyl ester (0.10 mmol, 28 mg). The resulting reaction was heated to 80 0C and allowed to stir at this temperature for 15 hours, after which time the reaction mixture was cooled to room temperature and concentrated in vacuo. The resulting residue was reacted with TFA (0.5 ml_) for 10 minutes. The TFA solution was then concentrated in vacuo Xo provide a crude residue which was purified using reverse phase HPLC to provide Compound 5. |
With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; at 20℃; for 15h; | General procedure: To a solution of 2-bromo-thiazole-4-carboxylic acid (0.78 mmol, 0.16 g), DIEA (1.5 mmol, 0.26 mL) and HATU (0.78 mmol, 0.30 g) in DMF (4 mL) was added 4-(3-amino-pyridin-4-yl)-piperazine-1-carboxylic acid tert-butyl ester (0.78 mmol, 0.22 g). The reaction mixture was stirred at room temperature for about 15 h, and then concentrated in vacuo. The resulting residue was purified using column chromatography on silica gel (eluent: EtOAc) to provide the title compound as a yellow solid (0.23 g, 63% yield). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; | To a solution of 2-bromothiazole-4-carboxylic acid (2 5 g, 12.0 mmol) and 2,6- dimethoxyaniline (2.1 g, 13.2 mmol) in DCM (60 mL) was added DMAP (75 mg, 0.6 mmol) and EDCI (2.8 g, 14.4 mmol) at room temperature. The resulted mixture was stirred at room temperature overnight. The reaction solution was diluted with DCM (200 mL), washed with water (3*50 mL) and brine (100 mL), dried over anhydrous Na2S04 and concentrated in vacuo. The residue was purified by flash chromatography eluting with PE/ EtOAc (20/1-1/1) to afford the title compound as light yellow solid. NMR (400 MHz, DMSO-de) d 9.21 (s, 1H), 8.35 (s, 1H), 7.25 (t, J = 8.4 Hz, 1H), 6.71 (d, J = 8.4 Hz, 2H), 3.73 (s, 6H). LC-MS: m/z 342.9, 344.9 (M+H)+ |
A139839 [170235-26-4]
Methyl 2-bromothiazole-4-carboxylate
Similarity: 0.92
A241927 [100367-77-9]
Ethyl 2-bromothiazole-4-carboxylate
Similarity: 0.90
A127304 [943735-44-2]
2,5-Dibromothiazole-4-carboxylic acid
Similarity: 0.84
A113490 [1194374-25-8]
2-Bromo-5-methylthiazole-4-carboxylic acid
Similarity: 0.82
A127304 [943735-44-2]
2,5-Dibromothiazole-4-carboxylic acid
Similarity: 0.84
A113490 [1194374-25-8]
2-Bromo-5-methylthiazole-4-carboxylic acid
Similarity: 0.82
A227617 [103878-58-6]
5-Bromothiazole-4-carboxylic acid
Similarity: 0.74
A238144 [5198-87-8]
2-Chlorothiazole-4-carboxylic acid
Similarity: 0.73
A139839 [170235-26-4]
Methyl 2-bromothiazole-4-carboxylate
Similarity: 0.92
A241927 [100367-77-9]
Ethyl 2-bromothiazole-4-carboxylate
Similarity: 0.90
A127304 [943735-44-2]
2,5-Dibromothiazole-4-carboxylic acid
Similarity: 0.84